Osstec Limited – Trademark Portfolio
Entity Type: 99
Osstec Limited holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 4 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 5 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include ASCENT and OSSTEC. The owner is based in Indianapolis, IN.
Taft Stettinius & Hollister LLP
One Indiana Square, Suite 3500
Indianapolis, IN 46204
Showing of trademarks Trademarks
Trademark Classifications
Osstec Limited's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Osstec Limited have?
Osstec Limited has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned.
What trademark classes does Osstec Limited file in?
Osstec Limited files trademarks across 5 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 9 (Computers & Electronics). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Osstec Limited's most well-known trademarks?
Osstec Limited's registered trademark portfolio includes well-known marks such as ASCENT and OSSTEC. These are among 3 currently registered trademarks in the portfolio.
What is Osstec Limited's trademark registration success rate?
Osstec Limited has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.